Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant effect on CYP3A activity in healthy women
NCT05509816Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imlunestrant, sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity of Midazolam at Day 9 and Maximum Observed Concentration of Midazolam at Day 9. Started Sep 2022; status: completed.
02
Drugs
imlunestrant
Beyond the preview
Go deeper on NCT05509816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509816.